Case File
efta-01445152DOJ Data Set 10OtherEFTA01445152
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01445152
Pages
2
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
Special Statement for Uncovered Option Writers
Account No
Account Name
There are special risks associated with uncovered option writing which
expose the investor to potentially significant loss.
I understand that this type of strategy may not be suitable for all
customers approved for options transactions. I also
understand each of the following:
1. The potential loss of uncovered call writing is unlimited, since there is
no upper limit on a stock's price and the loss to
a writer of an uncovered call equals the stock price minus the exercise
price. The writer of an uncovered call is in an
extremely risky position, and may incur large losses if the value of the
underlying instrument increases above the
exercise price. Such a loss can exceed the equity in the call writer's
account.
2. The potential loss from writing uncovered put options is also
substantial. The writer of an uncovered put option bears a
risk of loss if the value of the underlying instrument declines below the
exercise price. However, since stock prices cannot
be lower than zero, the maximum loss is equal to the strike price of the put
sold less the premium received for that put.
Such loss could be substantial if there is a significant decline in the
value of the underlying instrument and can exceed the
equity in the put writer's account.
3. For combination writing, where the investor writes both a put and a call
on the same underlying instrument, the
potential risk is unlimited and can exceed the equity in the option writer's
account
4. Uncovered option writing is thus suitable only for the knowledgeable
investor who understands the risks, has the financial
capacity and willingness to incur potentially substantial losses and has
sufficient liquid assets to meet applicable margin
requirements. In this regard, if the value of the underlying instrument
moves against an uncovered writer's options
position, the investor's broker may request significant additional margin
payments. If an investor does not make such
margin payments, the broker may liquidate stock or options positions in the
investor's account, with little or no prior
notice in accordance with the investor's margin agreement.
5. The option writer may not be able to rely on the secondary market. If a
secondary market in options were to become unavailable,
investors could not engage in closing transactions, and an option writer
would remain obligated until expiration or assignment.
6. The writer of an American-style option is subject to being assigned an
exercise at any time after he has written the option
until the option expires. By contrast, the writer of a European-style option
is subject to exercise assignment only during
the exercise period.
NOTE: It is expected that the person(s) signing below will read the booklet
entitled Characteristics and Risks of Standardized
EFTA01445152
Options available from your broker. Particular attention is directed to the
chapter entitled "Risks of Buying and Writing Options." This
statement is not intended to enumerate all of the risks entailed in writing
uncovered options.
I have read and understand the above statement regarding the special risks
associated with uncovered option writing and
represent that such trading is suitable in light of my investment
objectives, which include speculation, as well as my financial
situation, risk tolerance and knowledge. I understand that you will rely on
the representations I have made herein and in
the Option Agreement and Approval Form I provided to you in determining
whether to approve my account for the options
strategies I have elected and I hereby certify the truth and accuracy of
such statements.
Signed
Signed
Signed
Signed
Signed
Approved for
ROP/Manager Approval
Uncovered Calls
Uncovered Puts
Date
Date
Date
Date
Date
Date
Deutsche Bank Securities Inc., a subsidiary of Deutsche Bank AG, conducts
investment banking and securities activities in the United States.
0 2017 Deutsche Bank AG. All rights reserved. WM179363 006418.120617
DBOPTS
DBOPTS
N4Gxxx968
Jeffrey Epstein
EFTA01445153
Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.